GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (LTS:0RUG) » Definitions » Short Percentage of Float

BioMerieux (LTS:0RUG) Short Percentage of Float


View and export this data going back to 2007. Start your Free Trial

What is BioMerieux Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BioMerieux's Short Percentage of Float

For the Diagnostics & Research subindustry, BioMerieux's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMerieux's Short Percentage of Float Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BioMerieux's Short Percentage of Float falls into.


BioMerieux (LTS:0RUG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (LTS:0RUG) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ERF XPAR:LBIRD XPAR:ALPRE TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT SHSE:603259 LH DGX RVTY MEDP CRL NTRA
Traded in Other Exchanges
BMXMF:USA BIMp:UK BIM:France EYWN:Germany BIM:Austria
Address
Marcy l’Etoile, Lyon, FRA, 69280
Website
http://www.biomerieux.com
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (LTS:0RUG) Headlines

No Headlines